Ask a research question about Sickle Cell Disease. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).
Do not include personal health information in your question. Questions and results are cached in your browser's local storage.
name: Sickle Cell Disease
creation_date: '2025-12-18T17:01:35Z'
updated_date: '2026-05-10T22:52:07Z'
category: Mendelian
parents:
- Hematological Disease
- Genetic Disease
disease_term:
preferred_term: sickle cell disease
term:
id: MONDO:0011382
label: sickle cell disease
mappings:
mondo_mappings:
- term:
id: MONDO:0011382
label: sickle cell disease
mapping_predicate: skos:exactMatch
mapping_source: ORPHA:232
mapping_justification: >-
Orphanet's cross-reference table lists "MONDO:0011382 | Exact" for the
ORPHA:232 sickle cell anemia structured record.
consistency:
- reference: ORPHA:232
consistent: CONSISTENT
notes: "MONDO:0011382 | Exact"
external_assertions:
- name: Orphanet sickle cell anemia structured record
source: Orphanet
assertion_type: structured_disease_record
external_id: ORPHA:232
url: http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=232
description: >-
Orphanet curates ORPHA:232 as the sickle cell anemia record, a severe
homozygous HbS form within sickle cell disease, and provides exact
cross-references to this entry's MONDO identifier plus OMIM, MeSH, MedDRA,
UMLS, and other registry identifiers.
evidence:
- reference: ORPHA:232
reference_title: "Sickle cell anemia (Orphanet structured-database record)"
supports: SUPPORT
evidence_source: OTHER
snippet: "ORPHA:232 Sickle cell anemia"
explanation: >-
The Orphanet structured record heading identifies ORPHA:232 as the sickle
cell anemia disease record.
- reference: ORPHA:232
reference_title: "Sickle cell anemia (Orphanet structured-database record)"
supports: SUPPORT
evidence_source: OTHER
snippet: "MONDO:0011382 | Exact"
explanation: >-
Orphanet maps ORPHA:232 exactly to the MONDO disease identifier used by
this entry.
- reference: ORPHA:232
reference_title: "Sickle cell anemia (Orphanet structured-database record)"
supports: SUPPORT
evidence_source: OTHER
snippet: "OMIM:603903 | Exact"
explanation: Orphanet lists OMIM:603903 as an exact cross-reference.
- reference: ORPHA:232
reference_title: "Sickle cell anemia (Orphanet structured-database record)"
supports: SUPPORT
evidence_source: OTHER
snippet: "MeSH:D000755 | Exact"
explanation: Orphanet lists MeSH:D000755 as an exact cross-reference.
inheritance:
- name: Autosomal recessive inheritance
inheritance_term:
preferred_term: Autosomal recessive inheritance
term:
id: HP:0000007
label: Autosomal recessive inheritance
description: >-
Orphanet records sickle cell anemia as autosomal recessive, consistent with
disease from biallelic pathogenic HBB alleles.
evidence:
- reference: ORPHA:232
reference_title: "Sickle cell anemia (Orphanet structured-database record)"
supports: SUPPORT
evidence_source: OTHER
snippet: "- Autosomal recessive"
explanation: Orphanet directly records autosomal recessive inheritance.
prevalence:
- population: Global population, 2021
percentage: 7.74 million people living with sickle cell disease
notes: >-
Global Burden of Disease 2021 estimates show substantial worldwide living
prevalence, with highest burden in sub-Saharan Africa and increasing total
case counts over time.
evidence:
- reference: PMID:37331373
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
The number of people living with sickle cell disease globally increased by 41·4% (38·3-44·9), from 5·46 million (4·62-6·45) in 2000 to 7·74 million (6·51-9·2) in 2021.
explanation: >-
This GBD 2021 systematic analysis provides the best current global living
prevalence estimate for sickle cell disease.
- population: Live births in 11 US Sickle Cell Data Collection states, 2016-2020
percentage: 4.83 per 10,000 live births (1 in 2,070)
notes: >-
In the same surveillance dataset, birth prevalence among non-Hispanic Black
newborns was 28.54 per 10,000 live births (1 in 350), showing the marked
population-specific burden of disease in the United States.
evidence:
- reference: PMID:38547025
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
SCD birth prevalence was 4.83 per 10,000 (one in every 2,070) live births and 28.54 per 10,000 (one in every 350) non-Hispanic Black newborns.
explanation: >-
This multistate newborn-screening analysis provides a contemporary
population-based US birth-prevalence estimate for sickle cell disease.
- population: Europe (Orphanet point prevalence)
percentage: 1-5 per 10,000
notes: >-
Orphanet classifies European point prevalence for sickle cell anemia in the
1-5 per 10,000 band.
evidence:
- reference: ORPHA:232
reference_title: "Sickle cell anemia (Orphanet structured-database record)"
supports: SUPPORT
evidence_source: OTHER
snippet: "1-5 / 10 000 | Europe | Point prevalence | PMID:2019"
explanation: >-
Orphanet's epidemiology table provides this European point-prevalence
class.
- population: United States (Orphanet point prevalence)
percentage: 1-5 per 10,000
notes: >-
Orphanet classifies United States point prevalence for sickle cell anemia in
the 1-5 per 10,000 band.
evidence:
- reference: ORPHA:232
reference_title: "Sickle cell anemia (Orphanet structured-database record)"
supports: SUPPORT
evidence_source: OTHER
snippet: "1-5 / 10 000 | United States | Point prevalence | PMID:20331952,INST"
explanation: >-
Orphanet's epidemiology table provides this United States point-prevalence
class.
- population: United States live births (Orphanet)
percentage: 1-5 per 10,000 live births
notes: >-
Orphanet classifies United States birth prevalence for sickle cell anemia in
the 1-5 per 10,000 live-birth band.
evidence:
- reference: ORPHA:232
reference_title: "Sickle cell anemia (Orphanet structured-database record)"
supports: SUPPORT
evidence_source: OTHER
snippet: "1-5 / 10 000 | United States | Prevalence at birth | PMID:17183567"
explanation: >-
Orphanet's epidemiology table provides this United States
prevalence-at-birth class.
progression:
- phase: Onset
age_range: All ages
notes: Orphanet records onset across all ages for sickle cell anemia.
evidence:
- reference: ORPHA:232
reference_title: "Sickle cell anemia (Orphanet structured-database record)"
supports: SUPPORT
evidence_source: OTHER
snippet: "Age of onset: All ages"
explanation: Orphanet records all ages as the age-of-onset category.
pathophysiology:
- name: Hemoglobin Polymerization
description: >
Deoxygenated HbS polymerizes into rigid fibers, deforming red
blood cells into sickle shape. HbS has glutamic acid to valine
substitution at position 6 of beta-globin.
biological_processes:
- preferred_term: protein polymerization
term:
id: GO:0051258
label: protein polymerization
- preferred_term: response to hypoxia
term:
id: GO:0001666
label: response to hypoxia
downstream:
- target: Red Blood Cell Sickling
description: HbS polymer formation deforms erythrocytes and drives sickling.
evidence:
- reference: PMID:29614632
reference_title: "Sickle cell dehydration: Pathophysiology and therapeutic applications."
supports: PARTIAL
snippet: "Due to the unique dependence of Hb S polymerization on cellular Hb S concentration, cell dehydration promotes polymerization and sickling."
explanation: HbS polymerization is concentration-dependent and leads to sickling.
- reference: PMID:3965046
reference_title: "Hemoglobin S polymerization: primary determinant of the hemolytic and clinical severity of the sickling syndromes."
supports: PARTIAL
snippet: Our results support the hypothesis that the intracellular polymerization of HbS is the primary determinant of the severity of both anemia and clinical symptomatology in the sickle hemoglobinopathies.
explanation: Establishes HbS polymerization as the primary determinant of clinical severity in sickling syndromes.
- name: Red Blood Cell Sickling
description: >
Sickled RBCs are rigid and fragile, leading to hemolytic anemia
and shortened RBC lifespan (10-20 days vs normal 120 days).
cell_types:
- preferred_term: Red Blood Cell
term:
id: CL:0000232
label: erythrocyte
biological_processes:
- preferred_term: erythrocyte homeostasis
term:
id: GO:0034101
label: erythrocyte homeostasis
- preferred_term: positive regulation of erythrocyte clearance
term:
id: GO:0034108
label: positive regulation of erythrocyte clearance
downstream:
- target: Vaso-Occlusion
description: Rigid sickled erythrocytes increase microvascular obstruction and endothelial interactions.
- target: Chronic Hemolysis
description: Repeated membrane injury promotes erythrocyte destruction and clearance.
evidence:
- reference: PMID:29614632
reference_title: "Sickle cell dehydration: Pathophysiology and therapeutic applications."
supports: PARTIAL
snippet: "In double heterozygosis for Hb S and C (SC disease) dehydration is the determining factor in disease pathophysiology."
explanation: Cell dehydration promotes sickling and fragility of red blood cells.
- name: Vaso-Occlusion
description: >
Sickled cells adhere to vascular endothelium and obstruct
microcirculation, causing tissue ischemia and pain crises.
Inflammation amplifies adhesion.
cell_types:
- preferred_term: Endothelial Cell
term:
id: CL:0000115
label: endothelial cell
biological_processes:
- preferred_term: leukocyte adhesion to vascular endothelial cell
term:
id: GO:0061756
label: leukocyte adhesion to vascular endothelial cell
- preferred_term: positive regulation of cell adhesion
term:
id: GO:0045785
label: positive regulation of cell adhesion
downstream:
- target: Pain Crises
description: Microvascular obstruction causes ischemic vaso-occlusive pain episodes.
- target: Chronic Organ Damage
description: Recurrent vaso-occlusion causes ischemia-reperfusion injury in end organs.
evidence:
- reference: PMID:24277079
reference_title: "Heme triggers TLR4 signaling leading to endothelial cell activation and vaso-occlusion in murine sickle cell disease."
supports: PARTIAL
snippet: "intravascular hemolysis in SCD releases heme that activates endothelial TLR4 signaling leading to WPB degranulation, NF-κB activation, and vaso-occlusion."
explanation: Heme released from hemolysis triggers TLR4 signaling on endothelial cells, leading to Weibel-Palade body degranulation and release of P-selectin and von Willebrand factor, which promote adhesion and vaso-occlusion.
- name: Chronic Hemolysis
description: >
Intravascular hemolysis releases free hemoglobin, scavenging
nitric oxide and causing endothelial dysfunction, pulmonary
hypertension, and stroke risk.
biological_processes:
- preferred_term: nitric oxide metabolic process
term:
id: GO:0046209
label: nitric oxide metabolic process
- preferred_term: response to oxidative stress
term:
id: GO:0006979
label: response to oxidative stress
downstream:
- target: Chronic Organ Damage
description: Nitric oxide depletion and oxidative stress drive progressive endothelial and tissue injury.
- target: Chronic Hemolytic Anemia
description: Sustained erythrocyte destruction contributes to chronic hemolytic anemia.
evidence:
- reference: PMID:15998894
reference_title: "Dysregulated arginine metabolism, hemolysis-associated pulmonary hypertension, and mortality in sickle cell disease."
supports: SUPPORT
snippet: "hemolysis contributes to reduced nitric oxide bioavailability and endothelial dysfunction via release of erythrocyte arginase, which limits arginine bioavailability, and release of erythrocyte hemoglobin, which scavenges nitric oxide."
explanation: Hemolysis releases both arginase (which depletes L-arginine, the substrate for nitric oxide synthesis) and free hemoglobin (which directly scavenges nitric oxide), leading to endothelial dysfunction and pulmonary hypertension.
- reference: PMID:15998894
reference_title: "Dysregulated arginine metabolism, hemolysis-associated pulmonary hypertension, and mortality in sickle cell disease."
supports: PARTIAL
snippet: "The ratios of arginine to ornithine and arginine to ornithine plus citrulline are independently associated with pulmonary hypertension and increased mortality in patients with sickle cell disease."
explanation: Low arginine bioavailability due to increased arginase activity is directly associated with pulmonary hypertension severity and mortality risk in SCD patients.
- name: Chronic Organ Damage
description: >
Repeated vaso-occlusion and ischemia-reperfusion injury cause
progressive damage to spleen, kidneys, lungs, and brain.
biological_processes:
- preferred_term: response to ischemia
term:
id: GO:0002931
label: response to ischemia
- preferred_term: cellular response to oxidative stress
term:
id: GO:0034599
label: cellular response to oxidative stress
phenotypes:
- name: Pain Crises
category: Musculoskeletal
frequency: VERY_FREQUENT
diagnostic: true
notes: Acute vaso-occlusive episodes
phenotype_term:
preferred_term: Pain Crisis
term:
id: HP:0012531
label: Pain
evidence:
- reference: PMID:24277079
reference_title: "Heme triggers TLR4 signaling leading to endothelial cell activation and vaso-occlusion in murine sickle cell disease."
supports: PARTIAL
snippet: "Heme rapidly (5 minutes) mobilized Weibel-Palade body (WPB) P-selectin and VWF onto EC and vessel wall surfaces and activated EC nuclear factor κB (NF-κB)."
explanation: Heme-induced rapid release of adhesion molecules (P-selectin and von Willebrand factor) triggers vaso-occlusion, which causes pain crises in sickle cell disease.
- reference: ORPHA:232
reference_title: "Sickle cell anemia (Orphanet structured-database record)"
supports: SUPPORT
evidence_source: OTHER
snippet: "HP:0012531 | Pain | Very frequent (99-80%)"
explanation: >-
Orphanet independently records pain as a very frequent HPO phenotype of
sickle cell anemia.
- name: Chronic Hemolytic Anemia
category: Hematologic
frequency: OBLIGATE
phenotype_term:
preferred_term: Chronic hemolytic anemia
term:
id: HP:0004870
label: Chronic hemolytic anemia
evidence:
- reference: PMID:15998894
reference_title: "Dysregulated arginine metabolism, hemolysis-associated pulmonary hypertension, and mortality in sickle cell disease."
supports: PARTIAL
snippet: "hemolysis contributes to reduced nitric oxide bioavailability and endothelial dysfunction via release of erythrocyte arginase"
explanation: Chronic hemolysis is a hallmark feature of sickle cell disease.
- reference: ORPHA:232
reference_title: "Sickle cell anemia (Orphanet structured-database record)"
supports: SUPPORT
evidence_source: OTHER
snippet: "HP:0004870 | Chronic hemolytic anemia | Obligate (100%)"
explanation: >-
Orphanet records chronic hemolytic anemia as an obligate phenotype of
sickle cell anemia.
- name: Jaundice
category: Hematologic
frequency: FREQUENT
notes: From chronic hemolysis
phenotype_term:
preferred_term: Jaundice
term:
id: HP:0000952
label: Jaundice
evidence:
- reference: ORPHA:232
reference_title: "Sickle cell anemia (Orphanet structured-database record)"
supports: SUPPORT
evidence_source: OTHER
snippet: "HP:0000952 | Jaundice | Frequent (79-30%)"
explanation: Orphanet records jaundice as a frequent phenotype.
- name: Splenic Sequestration
category: Hematologic
frequency: OCCASIONAL
notes: Medical emergency in children
phenotype_term:
preferred_term: Splenomegaly
term:
id: HP:0001744
label: Splenomegaly
- name: Abnormality of the Spleen
category: Hematologic
frequency: FREQUENT
notes: Broad Orphanet spleen phenotype complementing specific splenic sequestration risk.
phenotype_term:
preferred_term: Abnormality of the spleen
term:
id: HP:0001743
label: Abnormality of the spleen
evidence:
- reference: ORPHA:232
reference_title: "Sickle cell anemia (Orphanet structured-database record)"
supports: SUPPORT
evidence_source: OTHER
snippet: "HP:0001743 | Abnormality of the spleen | Frequent (79-30%)"
explanation: Orphanet records spleen abnormality as a frequent phenotype.
- name: Acute Chest Syndrome
category: Respiratory
frequency: OCCASIONAL
notes: Leading cause of death
phenotype_term:
preferred_term: Respiratory Distress
term:
id: HP:0002098
label: Respiratory distress
evidence:
- reference: PMID:24620350
reference_title: "Heme-induced neutrophil extracellular traps contribute to the pathogenesis of sickle cell disease."
supports: PARTIAL
snippet: "Sickle cell disease (SCD) is characterized by recurring episodes of vascular occlusion in which neutrophil activation plays a major role. The disease is associated with chronic hemolysis with elevated cell-free hemoglobin and heme."
explanation: Neutrophil activation and hemolysis contribute to vascular occlusion and acute complications like acute chest syndrome.
- reference: PMID:24620350
reference_title: "Heme-induced neutrophil extracellular traps contribute to the pathogenesis of sickle cell disease."
supports: PARTIAL
snippet: "we have identified a novel role for heme in the induction of neutrophil extracellular trap (NET) formation in SCD. NETs are decondensed chromatin decorated by granular enzymes and are released by activated neutrophils."
explanation: Heme triggers neutrophil extracellular trap formation, which contributes to acute lung injury and acute chest syndrome in sickle cell disease.
- name: Chest Pain
category: Respiratory
frequency: FREQUENT
phenotype_term:
preferred_term: Chest pain
term:
id: HP:0100749
label: Chest pain
evidence:
- reference: ORPHA:232
reference_title: "Sickle cell anemia (Orphanet structured-database record)"
supports: SUPPORT
evidence_source: OTHER
snippet: "HP:0100749 | Chest pain | Frequent (79-30%)"
explanation: Orphanet records chest pain as a frequent phenotype.
- name: Stroke
category: Neurological
frequency: OCCASIONAL
notes: Children and adults at risk
phenotype_term:
preferred_term: Ischemic Stroke
term:
id: HP:0002140
label: Ischemic stroke
evidence:
- reference: ORPHA:232
reference_title: "Sickle cell anemia (Orphanet structured-database record)"
supports: SUPPORT
evidence_source: OTHER
snippet: "HP:0002140 | Ischemic stroke | Occasional (29-5%)"
explanation: Orphanet records ischemic stroke as an occasional phenotype.
- name: Priapism
category: Urological
frequency: OCCASIONAL
notes: In males
phenotype_term:
preferred_term: Priapism
term:
id: HP:0200023
label: Priapism
evidence:
- reference: ORPHA:232
reference_title: "Sickle cell anemia (Orphanet structured-database record)"
supports: SUPPORT
evidence_source: OTHER
snippet: "HP:0200023 | Priapism | Occasional (29-5%)"
explanation: Orphanet records priapism as an occasional phenotype.
- name: Leg Ulcers
category: Dermatological
frequency: OCCASIONAL
phenotype_term:
preferred_term: Skin Ulcer
term:
id: HP:0200042
label: Skin ulcer
evidence:
- reference: ORPHA:232
reference_title: "Sickle cell anemia (Orphanet structured-database record)"
supports: SUPPORT
evidence_source: OTHER
snippet: "HP:0200042 | Skin ulcer | Occasional (29-5%)"
explanation: Orphanet records skin ulcer as an occasional phenotype.
- name: Recurrent Infections
category: Immunologic
frequency: VERY_FREQUENT
notes: Functional asplenia and impaired splenic clearance increase infection risk.
phenotype_term:
preferred_term: Recurrent infections
term:
id: HP:0002719
label: Recurrent infections
evidence:
- reference: ORPHA:232
reference_title: "Sickle cell anemia (Orphanet structured-database record)"
supports: SUPPORT
evidence_source: OTHER
snippet: "HP:0002719 | Recurrent infections | Very frequent (99-80%)"
explanation: Orphanet records recurrent infections as a very frequent phenotype.
- name: Pigment Gallstones
category: Gastrointestinal
frequency: FREQUENT
notes: Chronic hemolysis increases bilirubin turnover and pigment gallstone risk.
phenotype_term:
preferred_term: Pigment gallstones
term:
id: HP:0011981
label: Pigment gallstones
evidence:
- reference: ORPHA:232
reference_title: "Sickle cell anemia (Orphanet structured-database record)"
supports: SUPPORT
evidence_source: OTHER
snippet: "HP:0011981 | Pigment gallstones | Frequent (79-30%)"
explanation: Orphanet records pigment gallstones as a frequent phenotype.
- name: Thrombocytosis
category: Hematologic
frequency: FREQUENT
phenotype_term:
preferred_term: Thrombocytosis
term:
id: HP:0001894
label: Thrombocytosis
evidence:
- reference: ORPHA:232
reference_title: "Sickle cell anemia (Orphanet structured-database record)"
supports: SUPPORT
evidence_source: OTHER
snippet: "HP:0001894 | Thrombocytosis | Frequent (79-30%)"
explanation: Orphanet records thrombocytosis as a frequent phenotype.
- name: Reticulocytosis
category: Hematologic
frequency: FREQUENT
phenotype_term:
preferred_term: Reticulocytosis
term:
id: HP:0001923
label: Reticulocytosis
evidence:
- reference: ORPHA:232
reference_title: "Sickle cell anemia (Orphanet structured-database record)"
supports: SUPPORT
evidence_source: OTHER
snippet: "HP:0001923 | Reticulocytosis | Frequent (79-30%)"
explanation: Orphanet records reticulocytosis as a frequent phenotype.
- name: Avascular Necrosis
category: Musculoskeletal
frequency: FREQUENT
notes: Vaso-occlusion can compromise bone blood supply.
phenotype_term:
preferred_term: Avascular necrosis
term:
id: HP:0010885
label: Avascular necrosis
evidence:
- reference: ORPHA:232
reference_title: "Sickle cell anemia (Orphanet structured-database record)"
supports: SUPPORT
evidence_source: OTHER
snippet: "HP:0010885 | Avascular necrosis | Frequent (79-30%)"
explanation: Orphanet records avascular necrosis as a frequent phenotype.
- name: Osteoporosis
category: Musculoskeletal
frequency: FREQUENT
phenotype_term:
preferred_term: Osteoporosis
term:
id: HP:0000939
label: Osteoporosis
evidence:
- reference: ORPHA:232
reference_title: "Sickle cell anemia (Orphanet structured-database record)"
supports: SUPPORT
evidence_source: OTHER
snippet: "HP:0000939 | Osteoporosis | Frequent (79-30%)"
explanation: Orphanet records osteoporosis as a frequent phenotype.
- name: Osteomyelitis
category: Musculoskeletal
frequency: FREQUENT
phenotype_term:
preferred_term: Osteomyelitis
term:
id: HP:0002754
label: Osteomyelitis
evidence:
- reference: ORPHA:232
reference_title: "Sickle cell anemia (Orphanet structured-database record)"
supports: SUPPORT
evidence_source: OTHER
snippet: "HP:0002754 | Osteomyelitis | Frequent (79-30%)"
explanation: Orphanet records osteomyelitis as a frequent phenotype.
- name: Chronic Kidney Disease
category: Renal
frequency: FREQUENT
notes: Recurrent vaso-occlusion and hemolysis contribute to sickle nephropathy.
phenotype_term:
preferred_term: Chronic kidney disease
term:
id: HP:0012622
label: Chronic kidney disease
evidence:
- reference: ORPHA:232
reference_title: "Sickle cell anemia (Orphanet structured-database record)"
supports: SUPPORT
evidence_source: OTHER
snippet: "HP:0012622 | Chronic kidney disease | Frequent (79-30%)"
explanation: Orphanet records chronic kidney disease as a frequent phenotype.
- name: Retinopathy
category: Ophthalmologic
frequency: FREQUENT
phenotype_term:
preferred_term: Retinopathy
term:
id: HP:0000488
label: Retinopathy
evidence:
- reference: ORPHA:232
reference_title: "Sickle cell anemia (Orphanet structured-database record)"
supports: SUPPORT
evidence_source: OTHER
snippet: "HP:0000488 | Retinopathy | Frequent (79-30%)"
explanation: Orphanet records retinopathy as a frequent phenotype.
- name: Pulmonary Arterial Hypertension
category: Cardiovascular
frequency: OCCASIONAL
phenotype_term:
preferred_term: Pulmonary arterial hypertension
term:
id: HP:0002092
label: Pulmonary arterial hypertension
evidence:
- reference: ORPHA:232
reference_title: "Sickle cell anemia (Orphanet structured-database record)"
supports: SUPPORT
evidence_source: OTHER
snippet: "HP:0002092 | Pulmonary arterial hypertension | Occasional (29-5%)"
explanation: >-
Orphanet records pulmonary arterial hypertension as an occasional
phenotype.
- name: Finger Dactylitis
category: Musculoskeletal
frequency: OCCASIONAL
phenotype_term:
preferred_term: Finger dactylitis
term:
id: HP:0031090
label: Finger dactylitis
evidence:
- reference: ORPHA:232
reference_title: "Sickle cell anemia (Orphanet structured-database record)"
supports: SUPPORT
evidence_source: OTHER
snippet: "HP:0031090 | Finger dactylitis | Occasional (29-5%)"
explanation: Orphanet records finger dactylitis as an occasional phenotype.
biochemical:
- name: Hemoglobin
presence: Decreased
context: "Chronic anemia, Hb typically 6-9 g/dL"
readouts:
- target: Chronic Hemolysis
relationship: READOUT_OF
direction: NEGATIVE
endpoint_context: MONITORING
regulatory_endpoint_refs:
- FDA-SE-adult-noncancer-078
- FDA-SE-pediatric-noncancer-054
interpretation: >-
Lower hemoglobin concentration reflects anemia from ongoing hemolysis and
marrow compensation limits.
biomarker_term:
preferred_term: hemoglobin measurement
term:
id: NCIT:C64848
label: Hemoglobin Measurement
evidence:
- reference: PMID:31199090
reference_title: "A Phase 3 Randomized Trial of Voxelotor in Sickle Cell Disease."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
The primary end point was the percentage of participants who had a
hemoglobin response, which was defined as an increase of more than 1.0 g
per deciliter from baseline at week 24 in the intention-to-treat analysis.
explanation: >-
This phase 3 SCD trial used hemoglobin response as a blood biomarker
endpoint, supporting hemoglobin concentration as a clinically measured
biomarker in SCD.
- reference: PMID:15998894
reference_title: "Dysregulated arginine metabolism, hemolysis-associated pulmonary hypertension, and mortality in sickle cell disease."
supports: PARTIAL
snippet: "hemolysis contributes to reduced nitric oxide bioavailability and endothelial dysfunction via release of erythrocyte arginase, which limits arginine bioavailability, and release of erythrocyte hemoglobin, which scavenges nitric oxide."
explanation: Chronic hemolysis releases free hemoglobin, contributing to anemia.
- name: Reticulocytes
presence: Elevated
context: Compensatory increased production
readouts:
- target: Chronic Hemolysis
relationship: READOUT_OF
direction: POSITIVE
endpoint_context: MONITORING
interpretation: >-
Elevated reticulocytes reflect marrow response to red-cell destruction in
chronic hemolysis.
biomarker_term:
preferred_term: reticulocyte count
term:
id: NCIT:C51947
label: Reticulocyte Count
evidence:
- reference: PMID:16291595
reference_title: "Lactate dehydrogenase as a biomarker of hemolysis-associated nitric oxide resistance, priapism, leg ulceration, pulmonary hypertension, and death in patients with sickle cell disease."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
In a cohort of 213 patients with sickle cell disease, we found
statistically significant associations of steady-state LDH with low levels
of hemoglobin and haptoglobin and high levels of reticulocytes,
bilirubin, plasma hemoglobin, aspartate aminotransferase, arginase, and
soluble adhesion molecules.
explanation: >-
This SCD cohort study supports elevated reticulocytes as part of the
hemolysis-associated biomarker profile.
- name: Bilirubin
presence: Elevated
context: Indirect, from hemolysis
readouts:
- target: Chronic Hemolysis
relationship: READOUT_OF
direction: POSITIVE
endpoint_context: MONITORING
interpretation: >-
Higher indirect bilirubin reflects heme catabolism from accelerated
red-cell breakdown.
biomarker_term:
preferred_term: indirect bilirubin measurement
term:
id: NCIT:C64483
label: Indirect Bilirubin Measurement
evidence:
- reference: PMID:31199090
reference_title: "A Phase 3 Randomized Trial of Voxelotor in Sickle Cell Disease."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
At week 24, the 1500-mg voxelotor group had significantly greater
reductions from baseline in the indirect bilirubin level and percentage of
reticulocytes than the placebo group.
explanation: >-
This phase 3 SCD trial used indirect bilirubin as a hemolysis biomarker
that changed with treatment.
- name: LDH
presence: Elevated
context: Hemolysis marker
readouts:
- target: Chronic Hemolysis
relationship: READOUT_OF
direction: POSITIVE
endpoint_context: PROGNOSTIC
interpretation: >-
Higher LDH reflects intravascular hemolysis and has been associated with
hemolysis-linked vasculopathy risk.
biomarker_term:
preferred_term: lactate dehydrogenase measurement
term:
id: NCIT:C64855
label: Lactate Dehydrogenase Measurement
synonyms:
- lactate dehydrogenase
evidence:
- reference: PMID:16291595
reference_title: "Lactate dehydrogenase as a biomarker of hemolysis-associated nitric oxide resistance, priapism, leg ulceration, pulmonary hypertension, and death in patients with sickle cell disease."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
We hypothesized that serum LDH may represent a convenient biomarker of
intravascular hemolysis and NO bioavailability, characterizing a clinical
subphenotype of hemolysis-associated vasculopathy.
explanation: >-
This human SCD cohort paper directly evaluates serum LDH as a biomarker of
intravascular hemolysis and nitric-oxide bioavailability.
- name: HbS
presence: Present
context: "Greater than 50% on hemoglobin electrophoresis"
readouts:
- target: Hemoglobin Polymerization
relationship: CORRELATES_WITH
direction: THRESHOLD_DEPENDENT
endpoint_context: DIAGNOSTIC
interpretation: >-
HbS fraction identifies the polymerizing hemoglobin substrate; risk
depends on genotype, oxygenation, concentration, and modifying hemoglobins.
biomarker_term:
preferred_term: hemoglobin S measurement
term:
id: NCIT:C122123
label: Hemoglobin S Measurement
synonyms:
- sickle hemoglobin
evidence:
- reference: PMID:31199090
reference_title: "A Phase 3 Randomized Trial of Voxelotor in Sickle Cell Disease."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Deoxygenated sickle hemoglobin (HbS) polymerization drives the
pathophysiology of sickle cell disease. Therefore, direct inhibition of
HbS polymerization has potential to favorably modify disease outcomes.
Voxelotor is an HbS polymerization inhibitor.
explanation: >-
This phase 3 SCD trial frames HbS polymerization as the proximal disease
biochemical process targeted by therapy.
- name: Fetal Hemoglobin
presence: Variable
context: >-
Higher HbF modifies SCD severity and is induced by therapies such as
hydroxyurea.
readouts:
- target: Hemoglobin Polymerization
relationship: CORRELATES_WITH
direction: NEGATIVE
endpoint_context: PHARMACODYNAMIC
interpretation: >-
Higher HbF is associated with reduced HbS polymerization and can serve as
a pharmacodynamic readout for HbF-inducing therapies.
biomarker_term:
preferred_term: hemoglobin F measurement
term:
id: NCIT:C92262
label: Hemoglobin F Measurement
synonyms:
- HbF
evidence:
- reference: PMID:18667698
reference_title: "DNA polymorphisms at the BCL11A, HBS1L-MYB, and beta-globin loci associate with fetal hemoglobin levels and pain crises in sickle cell disease."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Interindividual variation in fetal hemoglobin (HbF) expression is a known
and potentially heritable modifier of SCD severity. High HbF levels are
correlated with reduced morbidity and mortality.
explanation: >-
This human genetic association study supports HbF level as a clinically
meaningful modifier biomarker in SCD.
- reference: PMID:7715639
reference_title: "Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
In a previous open-label study of hydroxyurea therapy, the synthesis of
fetal hemoglobin increased in most patients with sickle cell anemia, with
only mild myelotoxicity.
explanation: >-
This sickle-cell anemia trial background supports HbF induction as a
treatment-linked biomarker.
genetic:
- name: HBB
association: Causative
notes: Glu6Val mutation (rs334)
evidence:
- reference: PMID:18667698
reference_title: "DNA polymorphisms at the BCL11A, HBS1L-MYB, and beta-globin loci associate with fetal hemoglobin levels and pain crises in sickle cell disease."
supports: PARTIAL
snippet: "Sickle cell disease (SCD) is a debilitating monogenic blood disorder with a highly variable phenotype characterized by severe pain crises, acute clinical events, and early mortality."
explanation: Confirms SCD is a monogenic blood disorder caused by HBB mutations.
- name: BCL11A
association: Modifier
notes: Regulates HbF levels
evidence:
- reference: PMID:18667698
reference_title: "DNA polymorphisms at the BCL11A, HBS1L-MYB, and beta-globin loci associate with fetal hemoglobin levels and pain crises in sickle cell disease."
supports: SUPPORT
snippet: "Common single nucleotide polymorphisms (SNPs) at the BCL11A and HBS1L-MYB loci have been implicated previously in HbF level variation"
explanation: BCL11A polymorphisms regulate fetal hemoglobin levels and modify sickle cell disease severity.
- name: HBS1L-MYB
association: Modifier
notes: Affects HbF levels
evidence:
- reference: PMID:18667698
reference_title: "DNA polymorphisms at the BCL11A, HBS1L-MYB, and beta-globin loci associate with fetal hemoglobin levels and pain crises in sickle cell disease."
supports: SUPPORT
snippet: "Together, common SNPs at the BCL11A, HBS1L-MYB, and beta-globin (HBB) loci account for >20% of the variation in HbF levels in SCD patients."
explanation: HBS1L-MYB locus polymorphisms are major modifiers of HbF levels in sickle cell disease.
environmental:
- name: Dehydration
notes: Triggers sickling
evidence:
- reference: PMID:29614632
reference_title: "Sickle cell dehydration: Pathophysiology and therapeutic applications."
supports: SUPPORT
snippet: "Cell dehydration is a distinguishing characteristic of sickle cell disease and an important contributor to disease pathophysiology. Due to the unique dependence of Hb S polymerization on cellular Hb S concentration, cell dehydration promotes polymerization and sickling."
explanation: Dehydration increases intracellular HbS concentration, promoting sickling.
- name: Hypoxia
notes: Promotes HbS polymerization
evidence:
- reference: PMID:29614632
reference_title: "Sickle cell dehydration: Pathophysiology and therapeutic applications."
supports: PARTIAL
snippet: "Each of these pathways exhibit unique characteristics in regulation by oxygen tension, intracellular and extracellular environment"
explanation: Low oxygen tension affects ion transport pathways that contribute to sickling.
- name: Cold Exposure
notes: Triggers vaso-occlusion
- name: High Altitude
notes: Low oxygen triggers crises
- name: Infections
notes: Common trigger for crises
treatments:
- name: Hydroxyurea
description: Increases HbF, reduces pain crises, first-line disease-modifying therapy.
evidence:
- reference: PMID:7715639
reference_title: "Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia."
supports: SUPPORT
snippet: "the 152 patients assigned to hydroxyurea treatment had lower annual rates of crises than the 147 patients given placebo (median, 2.5 vs. 4.5 crises per year, P < 0.001)"
explanation: Landmark RCT demonstrating hydroxyurea reduces painful crises by nearly half in sickle cell disease.
- name: Voxelotor
description: >-
HbS polymerization inhibitor formerly used to improve anemia; voluntarily
withdrawn from worldwide markets in 2024 due to postmarketing safety
concerns.
- name: Crizanlizumab
description: >-
P-selectin inhibitor for reducing vaso-occlusive crises; regulatory status
is jurisdiction-dependent after EU authorization revocation was recommended
in 2023 when STAND did not confirm benefit.
- name: L-Glutamine
description: Reduces oxidative stress in RBCs.
- name: Blood Transfusions
description: Chronic transfusions for stroke prevention, acute for severe anemia.
- name: Pain Management
description: NSAIDs, opioids for acute crises.
- name: Penicillin Prophylaxis
description: In children to prevent pneumococcal sepsis.
- name: Hematopoietic Stem Cell Transplant
description: Curative option for selected patients.
- name: Gene Therapy
description: Emerging curative approach (lovotibeglogene autotemcel).
evidence:
- reference: PMID:38661449
reference_title: "Exagamglogene Autotemcel for Severe Sickle Cell Disease."
supports: PARTIAL
snippet: "Exagamglogene autotemcel (exa-cel) is a nonviral cell therapy designed to reactivate fetal hemoglobin synthesis by means of ex vivo clustered regularly interspaced short palindromic repeats (CRISPR)-Cas9 gene editing of autologous CD34+ hematopoietic stem and progenitor cells (HSPCs) at the erythroid-specific enhancer region of BCL11A."
explanation: CRISPR-Cas9 gene editing of the BCL11A enhancer reactivates fetal hemoglobin, which prevents sickling.
- reference: PMID:38661449
reference_title: "Exagamglogene Autotemcel for Severe Sickle Cell Disease."
supports: PARTIAL
snippet: "Treatment with exa-cel eliminated vaso-occlusive crises in 97% of patients with sickle cell disease for a period of 12 months or more."
explanation: In phase 3 clinical trials, exagamglogene autotemcel (exa-cel) eliminated vaso-occlusive crises in 97% of patients for 12+ months, demonstrating high therapeutic efficacy.
classifications:
harrisons_chapter:
- classification_value: hematologic disorder
- classification_value: anemia
- classification_value: hereditary disease
datasets:
references:
- reference: DOI:10.1001/jama.2008.598
title: Evolution of Novel Small-Molecule Therapeutics Targeting Sickle Cell Vasculopathy
findings: []
- reference: DOI:10.1001/jama.294.1.81
title: Dysregulated Arginine Metabolism, Hemolysis-Associated Pulmonary Hypertension, and Mortality in Sickle Cell Disease
findings: []
- reference: DOI:10.1007/s00277-025-06216-1
title: A review on disease modifying pharmacologic therapies for sickle cell disease
findings: []
- reference: DOI:10.1016/j.bvth.2024.100015
title: 'Targeting the P-selectin/PSGL-1 pathway: discovery of disease-modifying therapeutics for disorders of thromboinflammation'
findings: []
- reference: DOI:10.1056/nejmoa2309676
title: Exagamglogene Autotemcel for Severe Sickle Cell Disease
findings: []
- reference: DOI:10.1080/17474086.2017.1327809
title: 'Heme-mediated cell activation: the inflammatory puzzle of sickle cell anemia'
findings: []
- reference: DOI:10.1182/blood-2013-04-495887
title: Heme triggers TLR4 signaling leading to endothelial cell activation and vaso-occlusion in murine sickle cell disease
findings: []
- reference: DOI:10.1182/blood-2013-10-529982
title: Heme-induced neutrophil extracellular traps contribute to the pathogenesis of sickle cell disease
findings: []
- reference: DOI:10.1182/hematology.2023000467
title: 'Pyruvate kinase activators: targeting red cell metabolism in sickle cell disease'
findings: []
- reference: DOI:10.3389/fphys.2024.1369120
title: 'Impact of intravascular hemolysis on functional and molecular alterations in the urinary bladder: implications for an overactive bladder in sickle cell disease'
findings: []
- reference: DOI:10.3389/fphys.2024.1474569
title: Therapeutics for sickle cell disease intravascular hemolysis
findings: []
- reference: DOI:10.3390/jcm13216404
title: The Current Role of Hydroxyurea in the Treatment of Sickle Cell Anemia
findings: []
Pathophysiology description (current understanding) SCD arises from a single missense variant in HBB (β6 Glu→Val) that promotes deoxygenated hemoglobin S (HbS) polymerization, driving red cell sickling, membrane injury, ion dysregulation, dehydration, and premature hemolysis. Intravascular hemolysis releases cell-free hemoglobin, heme, and erythrocyte arginase-1, which together mediate nitric oxide (NO) depletion, oxidative stress, endothelial activation, sterile inflammation, and a thromboinflammatory vasculopathy characterized by multicellular adhesion and vaso-occlusion. Hemolysis-derived heme triggers endothelial TLR4 signaling that rapidly releases Weibel–Palade body cargo (P-selectin and von Willebrand factor [VWF]), enhancing leukocyte rolling/adhesion and microvascular stasis. Heme and oxidized hemoglobin promote neutrophil extracellular traps (NETs), while emerging data implicate mast cell extracellular traps (MCETs) in neural and vascular injury that can exacerbate pain. These axes—HbS polymerization/sickling, hemolysis/NO depletion, adhesion/vaso-occlusion, and thromboinflammation—interact to cause acute crises (pain, acute chest) and chronic organ damage (pulmonary hypertension, renal and cerebrovascular disease). Foundational and recent studies support these mechanisms and identify therapeutic entry points, including HbF induction, heme scavenging, selectin blockade, metabolic modulation of red cells (PK activators), and gene editing that reactivates HbF. (ilboudo2022multiomicsapproachesto pages 20-24, belcher2014hemetriggerstlr4 pages 6-9, chen2014hemeinducedneutrophilextracellular pages 1-2, guarda2017hememediatedcellactivation pages 1-5)
1) Core Pathophysiology - Primary mechanisms - HbS polymerization and red-cell dehydration: Deoxygenated HbS forms long polymers that stiffen RBCs and promote membrane damage, repeated sickling, reactive oxygen species, disordered cation flux, activation of Gardos (KCNN4) and K–Cl cotransport, and RBC dehydration/density—thus increasing sickling propensity and hemolysis. (ilboudo2022multiomicsapproachesto pages 20-24) - Hemolysis, NO scavenging, arginase axis: Cell-free hemoglobin “reacts with and scavenges NO,” while erythrocyte arginase depletes L‑arginine, reducing NO synthesis; lower arginine:ornithine and arginine:(ornithine+citrulline) ratios correlate with pulmonary hypertension (PH) severity and mortality in adults with SCD. (morris2005dysregulatedargininemetabolism pages 7-8, kato2008evolutionofnovel pages 2-4, morris2005dysregulatedargininemetabolism pages 1-2, morris2005dysregulatedargininemetabolism pages 12-18, morris2005dysregulatedargininemetabolism pages 5-7) - Heme–TLR4–WPB pathway and adhesion: Free heme activates endothelial TLR4, inducing oxidative signaling and Weibel–Palade body degranulation (surface P‑selectin and VWF strings) within minutes, which promotes leukocyte rolling/adhesion and vaso‑occlusion; TLR4 inhibition (TAK‑242) and hemopexin/haptoglobin mitigate heme‑induced stasis in SCD mice. (belcher2014hemetriggerstlr4 pages 6-9) - Thromboinflammation: Heme/oxidized Hb and inflammatory stimuli trigger NET formation; “hemolysis releases cell free hemoglobin… [that] scavenges NO” and “oxidized hemoglobin and free heme can trigger a sterile inflammatory reaction involving TLR4 activation, and stimulates neutrophils to release NETs,” which contribute to acute lung injury and vaso‑occlusion. (chen2014hemeinducedneutrophilextracellular pages 1-2) - Selectin-mediated multicellular adhesion: Endothelial/platelet P‑ and E‑selectins and leukocyte PSGL‑1 drive tethering/rolling and firm adhesion of RBCs, leukocytes, and platelets, amplifying microvascular occlusion and ischemia-reperfusion injury. (escopy2024targetingthepselectinpsgl1 pages 10-12, belcher2014hemetriggerstlr4 pages 6-9) - MCETs and pain: In SCD murine models, PAD4‑dependent mast cell extracellular traps directly injure vasculature and nerves and promote vaso‑occlusion and hyperalgesia; PAD4 inhibition reduces vascular stasis and pain behaviors. (mahadevia2025areviewon pages 6-8)
Adhesion pathways: Selectins (P/E), PSGL‑1, VWF, integrins (ICAM/VCAM interactions) facilitate vaso‑occlusion. (escopy2024targetingthepselectinpsgl1 pages 10-12, belcher2014hemetriggerstlr4 pages 6-9)
Affected cellular processes
2) Key Molecular Players - Genes/Proteins (HGNC symbol) - HBB (β-globin; mutant HbS) – causal. (ilboudo2022multiomicsapproachesto pages 20-24) - BCL11A (erythroid enhancer target for HbF reactivation by gene editing). (frangoul2024exagamglogeneautotemcelfor pages 4-6) - SELP (P‑selectin), SELE (E‑selectin), SELPLG (PSGL‑1) – adhesion. (escopy2024targetingthepselectinpsgl1 pages 10-12) - VWF; WPB cargo. (belcher2014hemetriggerstlr4 pages 6-9) - TLR4 – heme sensing on endothelium. (belcher2014hemetriggerstlr4 pages 6-9) - ARG1 – arginase‑1; NOS isoforms (NOS3/eNOS). (morris2005dysregulatedargininemetabolism pages 7-8, morris2005dysregulatedargininemetabolism pages 5-7) - NOX components, PKC; NF‑κB – signaling. (belcher2014hemetriggerstlr4 pages 6-9) - PAD4 (PADI4) – trap formation (MCET/NET). (mahadevia2025areviewon pages 6-8)
Hemoglobin/heme (CHEBI:16136/30413), NO (CHEBI:16480), L‑arginine (CHEBI:29016), 2,3‑diphosphoglycerate (CHEBI:16001), ATP (CHEBI:15422). (chen2014hemeinducedneutrophilextracellular pages 1-2, kato2008evolutionofnovel pages 2-4, rubio2024thecurrentrole pages 9-11)
Cell types (CL terms)
Erythrocyte (CL:0000232), endothelial cell (CL:0000115), neutrophil (CL:0000775), mast cell (CL:0000097), platelet (CL:0000233), monocyte (CL:0000576). (chen2014hemeinducedneutrophilextracellular pages 1-2, belcher2014hemetriggerstlr4 pages 6-9, mahadevia2025areviewon pages 6-8)
Anatomical locations (UBERON)
3) Biological Processes (candidate GO annotations; evidence-based) - HbS polymerization and red-cell dehydration: “hemoglobin polymerization” (GO:0030492), “regulation of cation transport” (GO:0051924), “potassium ion transmembrane transport” (GO:0071805), “erythrocyte homeostasis” (GO:0034101). (ilboudo2022multiomicsapproachesto pages 20-24) - Endothelial activation/WPB exocytosis: “exocytosis” (GO:0006887), “endothelial cell activation” (GO:0042118), “response to heme” (GO:1903409). (belcher2014hemetriggerstlr4 pages 6-9) - Leukocyte/platelet adhesion and rolling: “leukocyte tethering or rolling” (GO:0050901), “cell adhesion mediated by integrin” (GO:0033627), “platelet activation” (GO:0030168). (escopy2024targetingthepselectinpsgl1 pages 10-12) - Hemolysis and NO pathway: “nitric oxide metabolic process” (GO:0046209), “arginine metabolic process” (GO:0006525), “regulation of blood pressure” (GO:0008217). (kato2008evolutionofnovel pages 2-4, morris2005dysregulatedargininemetabolism pages 7-8) - NET/MCET formation: “neutrophil extracellular trap formation” (GO:0036342), “chromatin decondensation” (GO:0031490). (chen2014hemeinducedneutrophilextracellular pages 1-2, mahadevia2025areviewon pages 6-8)
4) Cellular Components - Key loci of action: erythrocyte cytosol (HbS polymer), plasma (cell‑free Hb, heme), endothelial surface (P‑selectin/VWF strings), Weibel–Palade body, extracellular space (NETs/MCETs), caveolae/raft TLR4 signaling domains. (belcher2014hemetriggerstlr4 pages 6-9, chen2014hemeinducedneutrophilextracellular pages 1-2)
5) Disease Progression - Sequence of events 1) Deoxygenation → HbS polymerization → sickling, membrane injury, Ca2+ influx → Gardos/K–Cl activation → RBC dehydration/density. (ilboudo2022multiomicsapproachesto pages 20-24) 2) Vaso‑occlusion axis: Endothelial activation (heme–TLR4) and selectin/VWF upregulation → leukocyte/platelet/RBC adhesion → microvascular stasis and ischemia-reperfusion injury. (belcher2014hemetriggerstlr4 pages 6-9, escopy2024targetingthepselectinpsgl1 pages 10-12) 3) Hemolysis axis: Intravascular hemolysis releases cell‑free Hb/heme/arginase → NO scavenging + L‑arginine depletion → vasoconstriction, endothelial dysfunction, and PH risk. (kato2008evolutionofnovel pages 2-4, morris2005dysregulatedargininemetabolism pages 7-8) 4) Thromboinflammation: Heme/oxidized Hb drive NETs (and MCETs) that scaffold thrombosis and amplify occlusion and organ injury (e.g., lung). (chen2014hemeinducedneutrophilextracellular pages 1-2, mahadevia2025areviewon pages 6-8)
6) Phenotypic Manifestations (with mechanism links) - Acute painful vaso-occlusive crises (VOC): adhesion/selectin–PSGL‑1 axis and thromboinflammation (NETs/MCETs). (escopy2024targetingthepselectinpsgl1 pages 10-12, chen2014hemeinducedneutrophilextracellular pages 1-2, mahadevia2025areviewon pages 6-8) - Acute chest syndrome and acute lung injury: NETosis and heme–TLR4 endothelial activation. (chen2014hemeinducedneutrophilextracellular pages 1-2, belcher2014hemetriggerstlr4 pages 6-9) - Pulmonary hypertension: Hemolysis-associated NO scavenging and arginase-mediated L‑arginine depletion (risk of death markedly elevated with TRV ≥2.5 m/s). (morris2005dysregulatedargininemetabolism pages 7-8, kato2008evolutionofnovel pages 2-4) - Functional asplenia and infection susceptibility (encapsulated bacteria); infections trigger VOC/ACS and contribute substantially to morbidity/mortality, especially in LMICs. (ilboudo2022multiomicsapproachesto pages 20-24) - Organ-specific dysfunction from systemic NO depletion/oxidative stress (e.g., bladder overactivity with decreased p‑eNOS/p‑nNOS and increased NOX/oxidative markers in hemolysis models). (xue2024therapeuticsforsickle pages 1-2)
Evidence items and quotes (selected) - “Heme… activates endothelial TLR4 signaling leading to WPB degranulation, NF‑κB activation” and stasis; TAK‑242 reduced heme‑ or LPS‑induced stasis in SCD mice; hemopexin/haptoglobin abrogate heme effects. URL: https://doi.org/10.1182/blood-2013-04-495887 (Belcher et al., Blood, 2014). (belcher2014hemetriggerstlr4 pages 6-9) - “Hemolysis releases cell free hemoglobin (Hb)… Free hemoglobin reacts with and scavenges NO… Oxidized hemoglobin and free heme… stimulate neutrophils to release NETs.” URL: https://doi.org/10.1182/blood-2013-10-529982 (Chen et al., Blood, 2014). (chen2014hemeinducedneutrophilextracellular pages 1-2) - Low arginine bioavailability and PH/mortality: In adults with SCD, TRV ≥2.5 m/s conferred a risk ratio for death ≈7.4; lower arginine:ornithine and arginine:(ornithine+citrulline) ratios independently associated with mortality. URL: https://doi.org/10.1001/jama.294.1.81 (Morris et al., JAMA, 2005). (morris2005dysregulatedargininemetabolism pages 7-8, morris2005dysregulatedargininemetabolism pages 1-2, morris2005dysregulatedargininemetabolism pages 12-18)
Recent developments and latest research (2023–2024) - HbF reactivation by CRISPR-Cas9 (exagamglogene autotemcel, exa‑cel/Casgevy). In the phase 3 SCD study, among evaluable patients, 97% were free from severe VOCs for ≥12 consecutive months, and 100% were free from VOC hospitalizations for ≥12 months; safety consistent with busulfan-conditioning autologous HSPC transplant. URL: https://doi.org/10.1056/nejmoa2309676 (NEJM, 2024). (frangoul2024exagamglogeneautotemcelfor pages 4-6) - Selectin pathway: translational and clinical evidence establishes the biological centrality of the P‑selectin/PSGL‑1 axis; however, phase 3 results have been mixed (e.g., negative primary endpoint in STAND), prompting regulatory reassessment and regional revocation in 2023. URLs: https://doi.org/10.1016/j.bvth.2024.100015; (overview) and retrospective real‑world/center experiences. (escopy2024targetingthepselectinpsgl1 pages 10-12, rubio2024thecurrentrole pages 9-11) - RBC metabolic modulation (pyruvate kinase activators): Class effects include increased RBC ATP and decreased 2,3‑DPG, with early trials showing hemoglobin rises and improved RBC energetics; active development continued through 2023–2024. URL: Hematology ASH Education Program 2023 review https://doi.org/10.1182/hematology.2023000467. (rubio2024thecurrentrole pages 9-11) - Thromboinflammatory targets: NET/MCET pathways and complement/VWF/ADAMTS13 balance highlighted for future interventions; preclinical and early clinical programs include rADAMTS13 and hemopexin. (chen2014hemeinducedneutrophilextracellular pages 1-2, mahadevia2025areviewon pages 6-8) - Safety/regulatory updates for legacy agents: Crizanlizumab—mixed efficacy (phase 3 STAND negative) leading to EMA revocation (2023) and caution in observational cohorts; voxelotor—postmarketing safety concerns and mortality signals prompted withdrawal/suspension decisions in 2024. (rubio2024thecurrentrole pages 9-11)
Current applications and implementations - Hydroxyurea (cornerstone DMM): Increases HbF, lowers leukocytes/platelets and endothelial adhesion markers, improves NO signaling and reduces VOCs, ACS, transfusions, and mortality with long‑term use. Practical guidance emphasizes early initiation in children and use in adults with recurrent VOCs/ACS. URL: https://doi.org/10.3390/jcm13216404 (2024). (rubio2024thecurrentrole pages 9-11) - Selectin inhibition: While mechanistically compelling, clinical utility is uncertain due to mixed trial data; centers weigh risks, cost, and alternative DMMs; retrospective series report variable VOC trajectories and serious adverse events. (escopy2024targetingthepselectinpsgl1 pages 10-12, rubio2024thecurrentrole pages 9-11) - Gene therapy: Exa‑cel (Casgevy) has demonstrated high VOC‑free rates and pancellular HbF after myeloablative autologous HSPC gene editing; adoption considerations include myeloablative toxicity, infrastructure, and access disparities. (frangoul2024exagamglogeneautotemcelfor pages 4-6) - PK activators: Ongoing phase 2/3 programs (mitapivat, etavopivat) exploring clinically meaningful endpoints (Hb increase, VOCs), with phase 1/2 signals of biochemical correction (↑ATP, ↓2,3‑DPG) and hemoglobin rise. (rubio2024thecurrentrole pages 9-11)
Expert opinions and analysis (authoritative sources) - Mechanism-integrated view: Heme acts as a master DAMP; endothelial TLR4 activation is a proximal switch for WPB release and adhesion, providing rationale for heme scavenging or TLR4 pathway interventions. (belcher2014hemetriggerstlr4 pages 6-9) - NO pathway as a determinant of the “hemolytic phenotype”: Clinical associations of arginine dysregulation with PH and mortality argue for biomarker‑guided strategies and substrate/enzyme‑targeted adjuvant therapy in selected patients. (morris2005dysregulatedargininemetabolism pages 7-8, kato2008evolutionofnovel pages 2-4) - Thromboinflammation: Targeting NETs/MCETs and platelet–neutrophil/adhesion modules may complement HbF‑based and metabolic strategies; preclinical proof supports combined anti‑adhesive and anti‑DAMP therapies. (chen2014hemeinducedneutrophilextracellular pages 1-2, escopy2024targetingthepselectinpsgl1 pages 10-12, mahadevia2025areviewon pages 6-8)
Relevant statistics and data (recent and landmark) - Exa‑cel phase 3 (SCD): 97% (29/30) free from severe VOCs ≥12 months; 100% (30/30) free from VOC hospitalizations ≥12 months; median follow‑up 19.3 months. URL: https://doi.org/10.1056/nejmoa2309676 (NEJM, 2024). (frangoul2024exagamglogeneautotemcelfor pages 4-6) - Hemolysis–PH–mortality: TRV ≥2.5 m/s carried ~7.4× risk of death; low arginine:ornithine and low global arginine bioavailability independently associated with mortality (risk ratios roughly 2–3.6 depending on metric). URL: https://doi.org/10.1001/jama.294.1.81 (JAMA, 2005). (morris2005dysregulatedargininemetabolism pages 7-8, morris2005dysregulatedargininemetabolism pages 1-2, morris2005dysregulatedargininemetabolism pages 12-18) - Heme–TLR4–WPB: In murine SCD models, heme rapidly induced WPB degranulation and vaso‑occlusion; TAK‑242 reduced stasis (e.g., vehicle+heme 26.4% vs TAK‑242 9.3%). URL: https://doi.org/10.1182/blood-2013-04-495887 (Blood, 2014). (belcher2014hemetriggerstlr4 pages 6-9) - NETs in SCD: Heme‑driven NETosis implicated in acute lung injury and VOC in SCD models; DNase and ROS‑modulating strategies proposed. URL: https://doi.org/10.1182/blood-2013-10-529982 (Blood, 2014). (chen2014hemeinducedneutrophilextracellular pages 1-2) - Bladder dysfunction and NO signaling (model): Intravascular hemolysis increased urinary frequency and DSM hypercontractility with decreased p‑eNOS (Ser1177), p‑nNOS (Ser1417), and p‑VASP (Ser239), and increased NOX‑2, 3‑NT, and 4‑HNE in bladder. URL: https://doi.org/10.3389/fphys.2024.1369120 (Frontiers in Physiology, 2024). (xue2024therapeuticsforsickle pages 1-2)
Structured evidence summary | Mechanistic axis | Key molecules / cells | Mechanism (concise) | 2023–2024 highlights | Representative sources (journal, year) | |---|---|---:|---|---| | HbS polymerization & RBC dehydration | HbS, HbF, Gardos (KCNN4), K-Cl cotransport | Deoxygenated HbS polymerizes → filamentous polymers → RBC sickling, membrane damage, Ca2+ dysregulation → Gardos/K-Cl mediated K+ efflux → RBC dehydration and dense, rigid cells | Continued emphasis on HbF reactivation as protective; PK activators and metabolic approaches aim to alter 2,3‑DPG/ATP to reduce sickling (clinical programs active 2023–24) | (ilboudo2022multiomicsapproachesto pages 20-24, rubio2024thecurrentrole pages 9-11) | | Adhesion / selectins & WPB release | P‑selectin, E‑selectin, PSGL‑1, Weibel–Palade bodies (VWF, P‑selectin), platelets, endothelium | Endothelial/platelet selectin expression mediates RBC/leukocyte/platelet tethering and rolling → firm adhesion → microvascular occlusion | Therapeutics targeting P‑selectin/PSGL‑1 (crizanlizumab, inclacumab, pan‑selectin agents) show mechanistic benefit; clinical outcomes mixed leading to regulatory reassessments (2023–24) | (escopy2024targetingthepselectinpsgl1 pages 10-12, belcher2014hemetriggerstlr4 pages 6-9) | | Hemolysis → NO scavenging & arginase | Cell‑free hemoglobin, heme, arginase‑1, L‑arginine, NOS | Intravascular hemolysis releases cell‑free Hb that stoichiometrically scavenges NO; concomitant arginase release depletes L‑arginine, lowering NO production → vasoconstriction, endothelial dysfunction, PH | Strong clinical associations: low arginine:ornithine and low arginine:(ornithine+citrulline) ratios correlate with pulmonary hypertension and increased mortality in cohorts (2005 foundational data reinforced in reviews) | (morris2005dysregulatedargininemetabolism pages 8-9, kato2008evolutionofnovel pages 2-4) | | Heme → TLR4 signaling (endothelium) | Free heme, TLR4, NADPH oxidase (NOX), PKC, NF‑κB, WPB (P‑selectin, VWF) | Free heme activates endothelial TLR4 → oxidative signaling → Weibel–Palade body degranulation (P‑selectin, VWF) → rapid leukocyte/platelet recruitment and vaso‑occlusion | Murine SCD models: TLR4 blockade (TAK‑242) reduced heme‑induced stasis; hemopexin/haptoglobin mitigate heme effects — supports heme scavenging strategies | (belcher2014hemetriggerstlr4 pages 6-9, guarda2017hememediatedcellactivation pages 1-5) | | NETs & platelet–neutrophil aggregates | Neutrophils, NETs (citrullinated histones, DNA), platelets, HMGB1 | Heme/oxidized Hb and inflammatory signals trigger NETosis → extracellular chromatin scaffolds bind platelets and promote thrombosis and vaso‑occlusion; platelet–neutrophil crosstalk amplifies thromboinflammation | NET inhibition (DNase, ROS scavengers) and targeting platelet–neutrophil interactions are highlighted as potential interventions in recent reviews | (chen2014hemeinducedneutrophilextracellular pages 1-2, escopy2024targetingthepselectinpsgl1 pages 10-12) | | Mast cell extracellular traps (MCETs) | Mast cells, PAD4, citrullinated histones, nerve/vascular interfaces | Sickle microenvironment (heme/inflammation) induces MCET release → direct vascular and neural injury contributing to acute/chronic pain and vaso‑occlusion in models | Emerging 2024 data implicate PAD4‑dependent MCETs in vaso‑occlusion and pain; PAD4 inhibition ameliorated stasis and hyperalgesia in mice | (guarda2017hememediatedcellactivation pages 1-5, mahadevia2025areviewon pages 6-8) | | Complement / VWF axis & ADAMTS13 | Complement proteins, VWF, ADAMTS13, endothelium | Hemolysis/inflammation dysregulate VWF release and complement activation → microthrombotic injury; restoring ADAMTS13 or modulating complement may reduce organ injury | Preclinical and early clinical work (rADAMTS13, complement inhibitors, hemopexin) cited as promising approaches in 2023–24 reviews | (belcher2014hemetriggerstlr4 pages 6-9, mahadevia2025areviewon pages 6-8) | | PK activators (red‑cell metabolism) | Pyruvate kinase (PKR), 2,3‑DPG, ATP (RBC) | PK activators increase RBC ATP and lower 2,3‑DPG → higher O2 affinity, reduced HbS polymerization tendency, improved RBC deformability and hydration | 2023–24: multiple PK activators (mitapivat, etavopivat, AG‑946) progressed in trials; phase‑1/2 signals show ↑Hb and biochemical shifts (↓2,3‑DPG, ↑ATP) | (rubio2024thecurrentrole pages 9-11, escopy2024targetingthepselectinpsgl1 pages 10-12) | | Gene therapy (exa‑cel) approvals & outcomes | BCL11A editing, CD34+ HSPCs, CRISPR‑Cas9 | Ex vivo CRISPR editing of BCL11A erythroid enhancer → reactivation of γ‑globin (HbF) in erythroid lineage → reduced sickling and VOCs | Exa‑cel (Casgevy) demonstrated high rates of freedom from severe VOCs and durable HbF induction in phase‑3 data; regulatory approvals occurred in 2023 (UK, USA) with published NEJM outcomes (2024) | (frangoul2024exagamglogeneautotemcelfor pages 4-6) | | Selectin inhibition — mixed evidence | Crizanlizumab, inclacumab, rivipansel, sevuparin | Blocking P‑selectin/PSGL‑1 reduces multicellular adhesion and theoretically prevents VOCs; clinical benefit depends on trial/context and endpoints | Crizanlizumab showed VOC reduction in earlier trials but Phase‑3 STAND failed to meet primary endpoint leading to regulatory reassessments (2023–24); other selectin agents show variable results | (escopy2024targetingthepselectinpsgl1 pages 10-12, rubio2024thecurrentrole pages 9-11) | | Voxelotor (Hb‑oxygen affinity modifier) withdrawal signals | Voxelotor (Oxbryta), hemoglobin stabilization | Increases Hb by stabilizing oxygenated HbS (↓polymerization) improving anemia metrics | Approved earlier (2019/2022 regulatory actions), but 2024–2025 safety signal reports and registry/FAERS analyses prompted market withdrawal/reevaluation due to mortality and safety concerns in post‑approval data | (rubio2024thecurrentrole pages 9-11) | | Infection / functional asplenia & global burden | Splenic dysfunction, encapsulated bacteria, adaptive/innate immune defects | Functional asplenia + immune defects → high risk for invasive infection; infections also trigger VOCs and acute chest syndrome | Reviews (2023–24) emphasize infection as major morbidity/mortality driver in LMICs and the persistent care gap for prophylaxis/vaccination | (ilboudo2022multiomicsapproachesto pages 20-24, rubio2024thecurrentrole pages 9-11) | | Bladder / organ NO signaling with hemolysis | eNOS, nNOS, VASP, NOX enzymes, oxidative markers | Hemolysis reduces NO signaling (cell‑free Hb + arginase), increases oxidative stress → organ‑specific endothelial / smooth muscle dysfunction (e.g., bladder overactivity) | 2024 experimental work links intravascular hemolysis to reduced phosphorylated eNOS/nNOS and increased NOX/oxidative markers in bladder models, supporting systemic NO‑depletion effects on organs | (morris2005dysregulatedargininemetabolism pages 8-9, xue2024therapeuticsforsickle pages 1-2) |
Table: Concise table linking core sickle cell disease mechanistic axes to key molecules, short mechanisms, 2023–2024 developments, and representative source citations (context IDs) useful for knowledge‑base curation and evidence mapping.
Gene/protein annotations (HGNC) with ontology terms (examples) - HBB (HGNC:4827): hemoglobin complex (GO:0005833); hemoglobin polymerization (GO:0030492). Evidence: HbS polymerization drives sickling. (ilboudo2022multiomicsapproachesto pages 20-24) - BCL11A (HGNC:13222): regulation of hemoglobin F expression; target of exa‑cel gene editing to reactivate γ‑globin. (frangoul2024exagamglogeneautotemcelfor pages 4-6) - TLR4 (HGNC:11848): toll-like receptor signaling pathway (GO:0002224); response to heme (GO:1903409). (belcher2014hemetriggerstlr4 pages 6-9) - SELP/SELE/SELPLG (HGNC:10720/10719/10753): leukocyte tethering or rolling (GO:0050901), cell adhesion (GO:0007155). (escopy2024targetingthepselectinpsgl1 pages 10-12) - ARG1 (HGNC:663): arginine metabolic process (GO:0006525); negative regulation of nitric oxide biosynthetic process (GO:0046209 context). (morris2005dysregulatedargininemetabolism pages 7-8) - VWF (HGNC:12726): blood coagulation (GO:0007596); Weibel–Palade body (GO:0042582). (belcher2014hemetriggerstlr4 pages 6-9) - PADI4 (HGNC:18350): protein citrullination; neutrophil extracellular trap formation (GO:0036342). (mahadevia2025areviewon pages 6-8)
Phenotype associations (HP terms; examples) - HP:0002092 Acute chest syndrome (NET/adhesion/heme–TLR4). (chen2014hemeinducedneutrophilextracellular pages 1-2, belcher2014hemetriggerstlr4 pages 6-9) - HP:0001945 Hemolytic anemia (HbS polymerization/hemolysis). (ilboudo2022multiomicsapproachesto pages 20-24) - HP:0002905 Pulmonary hypertension (NO scavenging/arginase). (morris2005dysregulatedargininemetabolism pages 7-8, kato2008evolutionofnovel pages 2-4) - HP:0002093 Recurrent infections/functional asplenia (immune dysfunction). (ilboudo2022multiomicsapproachesto pages 20-24) - HP:0001873 Pain crisis (adhesion/thromboinflammation/MCETs). (escopy2024targetingthepselectinpsgl1 pages 10-12, mahadevia2025areviewon pages 6-8)
Cell type involvement (CL terms; examples) - Erythrocytes (CL:0000232) – HbS polymerization/ion transport/hemolysis. (ilboudo2022multiomicsapproachesto pages 20-24) - Endothelial cells (CL:0000115) – TLR4 activation/WPB release. (belcher2014hemetriggerstlr4 pages 6-9) - Neutrophils (CL:0000775) – NETosis and adhesion. (chen2014hemeinducedneutrophilextracellular pages 1-2) - Mast cells (CL:0000097) – MCETs in neural/vascular injury and pain. (mahadevia2025areviewon pages 6-8) - Platelets (CL:0000233) – adhesion/aggregate with NETs. (escopy2024targetingthepselectinpsgl1 pages 10-12)
Anatomical locations (UBERON; examples) - Microvasculature (UBERON:0001981), lung (UBERON:0002048), kidney (UBERON:0002113), spleen (UBERON:0002106), bladder (UBERON:0001255). (belcher2014hemetriggerstlr4 pages 6-9, chen2014hemeinducedneutrophilextracellular pages 1-2, xue2024therapeuticsforsickle pages 1-2)
Chemical entities (CHEBI; examples) - Heme (CHEBI:30413), nitric oxide (CHEBI:16480), L‑arginine (CHEBI:29016), ATP (CHEBI:15422), 2,3‑DPG (CHEBI:16001). (chen2014hemeinducedneutrophilextracellular pages 1-2, kato2008evolutionofnovel pages 2-4, rubio2024thecurrentrole pages 9-11)
Citations (URLs and publication dates) - Belcher et al., Blood, 2014 (Jan). Heme–TLR4–WPB/adhesion link in SCD. URL: https://doi.org/10.1182/blood-2013-04-495887 (belcher2014hemetriggerstlr4 pages 6-9) - Chen et al., Blood, 2014 (Jun). Hemolysis → NO scavenging; heme → NETs/acute lung injury. URL: https://doi.org/10.1182/blood-2013-10-529982 (chen2014hemeinducedneutrophilextracellular pages 1-2) - Morris et al., JAMA, 2005 (Jul). Arginase/NO pathway, PH and mortality risk. URL: https://doi.org/10.1001/jama.294.1.81 (morris2005dysregulatedargininemetabolism pages 7-8, morris2005dysregulatedargininemetabolism pages 1-2, morris2005dysregulatedargininemetabolism pages 12-18) - Frangoul et al., NEJM, 2024 (May). Exa‑cel phase 3 outcomes. URL: https://doi.org/10.1056/nejmoa2309676 (frangoul2024exagamglogeneautotemcelfor pages 4-6) - Escopy & Chaikof, Blood Vessels, Thrombosis & Hemostasis, 2024 (Sep). Selectin pathway therapeutics overview. URL: https://doi.org/10.1016/j.bvth.2024.100015 (escopy2024targetingthepselectinpsgl1 pages 10-12) - Rubio & Marina, J Clin Med, 2024 (Oct). Hydroxyurea role; regulatory context for crizanlizumab/voxelotor; PK activators overview. URL: https://doi.org/10.3390/jcm13216404 (rubio2024thecurrentrole pages 9-11) - Silveira et al., Front Physiol, 2024 (Jul). Hemolysis → bladder NO signaling and oxidative stress. URL: https://doi.org/10.3389/fphys.2024.1369120 (xue2024therapeuticsforsickle pages 1-2)
Notes on evidence strength and gaps - Landmark mechanistic data (Belcher; Chen) and clinical associations (Morris; Kato/Gladwin) remain foundational. 2023–2024 contributions strengthen translational axes (selectin therapeutics) and show transformative efficacy with exa‑cel for severe SCD. Mixed outcomes and evolving safety signals for selectin inhibitors and Hb‑oxygen affinity modifiers highlight the need for robust, event‑driven endpoints and long‑term pharmacovigilance. (escopy2024targetingthepselectinpsgl1 pages 10-12, rubio2024thecurrentrole pages 9-11, frangoul2024exagamglogeneautotemcelfor pages 4-6)
References
(ilboudo2022multiomicsapproachesto pages 20-24): Y Ilboudo. Multi-omics approaches to sickle cell disease heterogeneity. Unknown journal, 2022.
(belcher2014hemetriggerstlr4 pages 6-9): John D. Belcher, Chunsheng Chen, Julia Nguyen, Liming Milbauer, Fuad Abdulla, Abdu I. Alayash, Ann Smith, Karl A. Nath, Robert P. Hebbel, and Gregory M. Vercellotti. Heme triggers tlr4 signaling leading to endothelial cell activation and vaso-occlusion in murine sickle cell disease. Blood, 123 3:377-90, Jan 2014. URL: https://doi.org/10.1182/blood-2013-04-495887, doi:10.1182/blood-2013-04-495887. This article has 788 citations and is from a highest quality peer-reviewed journal.
(chen2014hemeinducedneutrophilextracellular pages 1-2): Grace Chen, Dachuan Zhang, Tobias A. Fuchs, Deepa Manwani, Denisa D. Wagner, and Paul S. Frenette. Heme-induced neutrophil extracellular traps contribute to the pathogenesis of sickle cell disease. Blood, 123 24:3818-27, Jun 2014. URL: https://doi.org/10.1182/blood-2013-10-529982, doi:10.1182/blood-2013-10-529982. This article has 421 citations and is from a highest quality peer-reviewed journal.
(guarda2017hememediatedcellactivation pages 1-5): Caroline Conceição da Guarda, Rayra Pereira Santiago, Luciana Magalhães Fiuza, Milena Magalhães Aleluia, Júnia Raquel Dutra Ferreira, Camylla Vilas Boas Figueiredo, Setondji Cocou Modeste Alexandre Yahouedehou, Rodrigo Mota de Oliveira, Isa Menezes Lyra, and Marilda de Souza Gonçalves. Heme-mediated cell activation: the inflammatory puzzle of sickle cell anemia. Expert Review of Hematology, 10:533-541, May 2017. URL: https://doi.org/10.1080/17474086.2017.1327809, doi:10.1080/17474086.2017.1327809. This article has 39 citations and is from a peer-reviewed journal.
(morris2005dysregulatedargininemetabolism pages 7-8): C. Morris, G. Kato, M. Poljakovic, Xunde Wang, W. Blackwelder, V. Sachdev, S. Hazen, E. Vichinsky, S. Morris, and M. Gladwin. Dysregulated arginine metabolism, hemolysis-associated pulmonary hypertension, and mortality in sickle cell disease. JAMA, 294 1:81-90, Jul 2005. URL: https://doi.org/10.1001/jama.294.1.81, doi:10.1001/jama.294.1.81. This article has 905 citations.
(kato2008evolutionofnovel pages 2-4): GJ Kato and MT Gladwin. Evolution of novel small-molecule therapeutics targeting sickle cell vasculopathy. JAMA, 300 22:2638-46, Dec 2008. URL: https://doi.org/10.1001/jama.2008.598, doi:10.1001/jama.2008.598. This article has 85 citations.
(morris2005dysregulatedargininemetabolism pages 1-2): C. Morris, G. Kato, M. Poljakovic, Xunde Wang, W. Blackwelder, V. Sachdev, S. Hazen, E. Vichinsky, S. Morris, and M. Gladwin. Dysregulated arginine metabolism, hemolysis-associated pulmonary hypertension, and mortality in sickle cell disease. JAMA, 294 1:81-90, Jul 2005. URL: https://doi.org/10.1001/jama.294.1.81, doi:10.1001/jama.294.1.81. This article has 905 citations.
(morris2005dysregulatedargininemetabolism pages 12-18): C. Morris, G. Kato, M. Poljakovic, Xunde Wang, W. Blackwelder, V. Sachdev, S. Hazen, E. Vichinsky, S. Morris, and M. Gladwin. Dysregulated arginine metabolism, hemolysis-associated pulmonary hypertension, and mortality in sickle cell disease. JAMA, 294 1:81-90, Jul 2005. URL: https://doi.org/10.1001/jama.294.1.81, doi:10.1001/jama.294.1.81. This article has 905 citations.
(morris2005dysregulatedargininemetabolism pages 5-7): C. Morris, G. Kato, M. Poljakovic, Xunde Wang, W. Blackwelder, V. Sachdev, S. Hazen, E. Vichinsky, S. Morris, and M. Gladwin. Dysregulated arginine metabolism, hemolysis-associated pulmonary hypertension, and mortality in sickle cell disease. JAMA, 294 1:81-90, Jul 2005. URL: https://doi.org/10.1001/jama.294.1.81, doi:10.1001/jama.294.1.81. This article has 905 citations.
(escopy2024targetingthepselectinpsgl1 pages 10-12): Samira Escopy and Elliot L. Chaikof. Targeting the p-selectin/psgl-1 pathway: discovery of disease-modifying therapeutics for disorders of thromboinflammation. Blood Vessels, Thrombosis & Hemostasis, 1:100015, Sep 2024. URL: https://doi.org/10.1016/j.bvth.2024.100015, doi:10.1016/j.bvth.2024.100015. This article has 21 citations.
(mahadevia2025areviewon pages 6-8): Himil Mahadevia, Ben Ponvilawan, Ujjwal Madan, Parth Sharma, Hana Qasim, and Anuj Shrestha. A review on disease modifying pharmacologic therapies for sickle cell disease. Annals of Hematology, 104:881-893, Jan 2025. URL: https://doi.org/10.1007/s00277-025-06216-1, doi:10.1007/s00277-025-06216-1. This article has 8 citations and is from a peer-reviewed journal.
(frangoul2024exagamglogeneautotemcelfor pages 4-6): Haydar Frangoul, Franco Locatelli, Akshay Sharma, Monica Bhatia, Markus Mapara, Lyndsay Molinari, Donna Wall, Robert I. Liem, Paul Telfer, Ami J. Shah, Marina Cavazzana, Selim Corbacioglu, Damiano Rondelli, Roland Meisel, Laurence Dedeken, Stephan Lobitz, Mariane de Montalembert, Martin H. Steinberg, Mark C. Walters, Michael J. Eckrich, Suzan Imren, Laura Bower, Christopher Simard, Weiyu Zhou, Fengjuan Xuan, Phuong Khanh Morrow, William E. Hobbs, and Stephan A. Grupp. Exagamglogene autotemcel for severe sickle cell disease. New England Journal of Medicine, 390:1649-1662, May 2024. URL: https://doi.org/10.1056/nejmoa2309676, doi:10.1056/nejmoa2309676. This article has 314 citations and is from a highest quality peer-reviewed journal.
(rubio2024thecurrentrole pages 9-11): Montserrat López Rubio and María Argüello Marina. The current role of hydroxyurea in the treatment of sickle cell anemia. Journal of Clinical Medicine, 13:6404, Oct 2024. URL: https://doi.org/10.3390/jcm13216404, doi:10.3390/jcm13216404. This article has 24 citations and is from a poor quality or predatory journal.
(xue2024therapeuticsforsickle pages 1-2): Jianyao Xue and Xiang-An Li. Therapeutics for sickle cell disease intravascular hemolysis. Frontiers in Physiology, Sep 2024. URL: https://doi.org/10.3389/fphys.2024.1474569, doi:10.3389/fphys.2024.1474569. This article has 1 citations and is from a poor quality or predatory journal.
(morris2005dysregulatedargininemetabolism pages 8-9): C. Morris, G. Kato, M. Poljakovic, Xunde Wang, W. Blackwelder, V. Sachdev, S. Hazen, E. Vichinsky, S. Morris, and M. Gladwin. Dysregulated arginine metabolism, hemolysis-associated pulmonary hypertension, and mortality in sickle cell disease. JAMA, 294 1:81-90, Jul 2005. URL: https://doi.org/10.1001/jama.294.1.81, doi:10.1001/jama.294.1.81. This article has 905 citations.